Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MNPR-101-Zr
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Monopar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Details : MNPR-101-Zr is a zirconium-labeled monoclonal antibody highly selective against uPAR, developed for treating triple-negative breast, colorectal, and pancreatic cancers.
Brand Name : MNPR-101-Zr
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 27, 2024
Lead Product(s) : MNPR-101-Zr
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Monopar Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?